Executive Vice President
Institute for Clinical Pharmacodynamics
Disclosure(s): Achaogen Inc.: Grant/Research Support; Adagio Therapeutics, Inc.: Grant/Research Support; AiCuris Anti-infective Cures AG: Grant/Research Support; Albany Medical College: Grant/Research Support; AN2 Therapeutics: Grant/Research Support; Antabio SAS: Grant/Research Support; Apogee Biologics, Inc.: Grant/Research Support; Arcutis Biotherapeutics, Inc.: Grant/Research Support; B. Braun Medical Inc.: Grant/Research Support; Basilea Pharmaceutica: Grant/Research Support; BioFire Diagnostics, LLC.: Grant/Research Support; Cidara Therapeutics Inc.: Grant/Research Support; Cipla USA: Grant/Research Support; Cumberland Pharmaceuticals Inc.: Grant/Research Support; Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc.: Grant/Research Support; Excalibur Pharmaceuticals Inc.: Grant/Research Support; Fedora Pharmaceuticals: Grant/Research Support; Genentech: Grant/Research Support; GlaxoSmithKline: Grant/Research Support; Global Antibiotic Research and Development Partnership: Grant/Research Support; Hoffmann-La Roche: Grant/Research Support; Inotrem: Grant/Research Support; Insmed Inc.: Grant/Research Support; Institute for Clinical Pharmacodynamics, Inc.: Ownership Interest; Iterum Therapeutics Limited: Grant/Research Support; Kaizen Bioscience: Grant/Research Support; Lassen Therapeutics Inc.: Grant/Research Support; Matinas Biopharma: Grant/Research Support; Meiji Seika Pharma Co., Ltd.: Grant/Research Support; Melinta Therapeutics: Grant/Research Support; Mutabilis: Grant/Research Support; Nabriva Therapeutics AG: Grant/Research Support; Novobiotic Pharmaceuticals LLC.: Grant/Research Support; Paratek Pharmaceuticals, Inc.: Grant/Research Support; Pfizer Inc.: Grant/Research Support; Praxis Precision Medicines, Inc.: Grant/Research Support; PTC Therapeutics: Grant/Research Support; PureTech LYT 100 Inc.: Grant/Research Support; Qpex Biopharma: Grant/Research Support; Renibus Therapeutics: Grant/Research Support; Sfunga Therapeutics: Grant/Research Support; Shionogi Inc.: Grant/Research Support; Spero Therapeutics: Grant/Research Support; Spruce Biosciences Inc.: Grant/Research Support; Suzhou Sinovent Pharmaceuticals Co.: Grant/Research Support; Theravance: Grant/Research Support; University of Wisconsin: Grant/Research Support; US Food and Drug Administration: Grant/Research Support; UT Southwestern: Grant/Research Support; ValanBio therapeutics, Inc.: Grant/Research Support; VenatoRx: Grant/Research Support; Zogenix International: Grant/Research Support
Dr. Christopher M. Rubino is one of three principal founders and the Executive Vice President, Pharmacometrics at the Institute for Clinical Pharmacodynamics (ICPD). He is also an Adjunct Assistant Research Professor in the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo. Dr. Rubino received his BS in Pharmacy from the University of Connecticut, his PharmD from the University at Buffalo, and completed a two-year post-doctoral fellowship in pediatric pharmacology at the Women’s Hospital of Greensboro.
He has served as a resource for pharmaceutical firms during the submission of adult- and pediatric-related filings to the Food and Drug Administration and European Medicines Agency across several therapeutic areas. His experience in this area spans the full breadth of activities from designing studies in adults and children to analysis of PK-PD data from such studies and, ultimately, to presentation at regulatory and international scientific meetings. He is a member of the International Society of Pharmacometrics and the American Society for Microbiology, and also serves as a member of the Antimicrobial Agents and Chemotherapy Editorial Board. He has authored more than 100 peer-reviewed publications and has assisted in refereeing numerous industry journals, including Diagnostic Microbiology and Infectious Diseases, The Journal of Clinical Pharmacology, and the Journal of Antimicrobial Chemotherapy.